[{"id":"538c5636-3e4e-4807-a35a-7c344d858490","acronym":"","url":"https://clinicaltrials.gov/study/NCT05208177","created_at":"2022-01-26T13:54:00.695Z","updated_at":"2024-07-02T16:36:09.697Z","phase":"Phase 2","brief_title":"A Study of SHR-1802 in Patients With Advanced Solid Tumor","source_id_and_acronym":"NCT05208177","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • famitinib (SHR 1020) • SHR-1802"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 04/22/2022","start_date":" 04/22/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-05-27"}]